Developments in biosimilars, increasing prevalence rate of Ulcerative Colitis, & changing lifestyle have resulted in boosting Ulcerative Colitis Drug market.

NEW YORK, NEW YORK, UNITED STATES, September 21, 2021 /EINPresswire.com/ -- The global ulcerative colitis drug market is forecast to reach USD 10.25 Billion by 2027, according to a new report by Reports and Data. Ulcerative colitis (UC) can be defined as an inflammatory bowel disease, which is chronic in nature. Some of the mentionable symptoms associated with the condition is inflammation, irritation, and ulcers in the lining of the colon. The disease does not have a cure, and patients of the condition experience revival of the symptoms. However, with the help of the right treatment, the condition and associated signs & symptoms can be effectively managed. The exact cause for the occurrence of the condition remains unknown. Previously stress and diet was suspected to be the cause for the occurrence of the disease. However, now it is known that stress and diet may aggravate the condition. Heredity and immune system malfunction are considered to be the possible cause for the occurrence of the disease. There are two main goals of UC treatment. The first is to control the symptom & enhance the comfort of patients and increasing the healing of colon. The second aim is to avoid more flare-ups. The focus of the treatment is to minimize & control the signs and symptoms of the disease. There are different types of drugs that may be prescribed by a doctor like Antibiotics, Corticosteroids, and Biologics, among others. In regards to region, Europe can be seen to occupy a prominent market share. The market share held by this region is the result of the high prevalence rate of the condition in this region, along with continuously expanding healthcare sector.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2379

Market Overview:

The pharma and healthcare industry has undergone a revolutionary change owing to the COVID-19 pandemic with individuals increasing their focus on health and wellness. Companies operating in the industry have invested heavily in clinical trials and research studies to develop medications to cater to the growing unmet clinical demand on a global level. Implementation of cutting-edge technology in healthcare sector and increasing investment in research and development have contributed significantly to revenue growth of the market in the recent past. In addition, availability of favorable health insurance and reimbursement policies have also positively impacted the healthcare sector with more and more individuals opting to get treatment at hospital and clinical facilities. Rapid development of novel drugs and pharmaceuticals, increasing incidence of lifestyle and chronic diseases, establishment of state-of-the-art healthcare facilities, and rising availability of over-the-counter medications have significantly contributed to the revenue growth of the market.

The report has gather vital information about recent mergers and acquisitions, joint ventures, collaborations, partnerships, brand promotions, R&D activities, and government and corporate deals, among others through extensive primary and secondary research. The report also offers detailed analysis of each competitor along with their financial standing, global market position, product portfolio, manufacturing and production capacity, and business expansion plans.

The report offers a comprehensive overview of the regional bifurcation of the market with respect to market share, market size, revenue growth, import/export, production and consumption patterns, macro and micro economic growth factors, regulatory framework, investment and funding opportunities, and presence of key players in each region including North America, Asia Pacific, Latin America, Europe, and Middle East & Africa. The report offers a country-wise analysis to further discuss the revenue growth and lucrative growth opportunities for the Ulcerative Colitis Drug market in these key regions.

Further key findings from the report suggest

• The Ulcerative Colitis Drug market held a market share of USD 6.79 Billion in the year 2018 that is forecasted to grow at a rate of 4.6% during the forecast period.

• In context to Drug Type, the Biologics segment generated the highest revenue of USD 2.78 Billion in 2018, with a CAGR of 4.6% during the forecast period. The effectiveness of Biologics in working in a selective manner, rather than affecting the whole body that results in reducing medication-related side effects and elevated preference among care providers and care users contributes to the revenue generated by this segment.

• In context to Route of Administration, the Oral segment is projected to witness a faster growth rate of 5.4% during the forecast period. The growth rate witnessed by the segment is attributed to the presence of strong pipeline products and continuous developments in various drugs, along with rising awareness about the condition. Increasing awareness about the disease results in early detection of the condition and increasing demand for 5-aminosalicylic acid, which is usually the first step of treatment.

• In context to Distribution Channel, the Hospitals Pharmacy segment held the largest market share of 45.0% in 2018, with a CAGR of 4.7% during the forecast period. The market share occupied by the Hospitals Pharmacy segment is resultant of the rising incidence rate of the condition, increase in the number of in-patient and out-patients, elevation in the number of hospitalization associated with the disease, which results in high demand for medications of the disease from this distribution channel.

• In regards to Application, the Ulcerative proctitis segment generated the highest revenue of USD 3.80 Billion in 2018, with a CAGR of 5.1% during the forecast period. The high incidence rate of the condition results in high demand for UC drug in this segment.

• In regards to the region, Asia Pacific is projected to witness the fastest growth rate of 5.1% during the forecast, which is expected to hold 8% of the market by 2027. The growth rate witnessed by the region is resultant of changing lifestyle that triggers the number of patients affected by this condition along with expansion of the health care sector and rising product approvals, which are supporting the market growth in this region.

• Key participants include Bausch Health Companies Inc. (Salix Pharmaceutical), AbbVie Inc., Johnson and Johnson, Boehringer Ingelheim GmbH, Novartis AG, Merck & Co., Teva Pharmaceuticals Ltd., Takeda Pharmaceuticals, Shire, Pfizer Inc.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2379

For the purpose of this report, Reports and Data have segmented the global Ulcerative Colitis Drug Type, Route of Administration, Distribution Channel, Application, and Region:

Drug Type Outlook (Revenue, USD Billion; 2016-2027)

• Biologics
• Corticosteroids
• Immunomodulators
• 5-aminosalicylic acid
• Immunosuppressant
• Biosimilars
• Others

Route of Administration Outlook (Revenue, USD Billion; 2016-2027)

• Oral
• Injectable

Distribution Channel Outlook (Revenue, USD Billion; 2016-2027)

• Hospitals Pharmacy
• Online Pharmacy
• Retail Pharmacy

Application Outlook (Revenue, USD Billion; 2016-2027)

• Proctosigmoiditis
• Ulcerative proctitis
• Pancolitis
• Left-sided colitis
• Acute severe ulcerative colitis

Regional Outlook (Revenue, USD Billion; 2016-2027)

• North America
• Europe
• Asia Pacific
• MEA
• Latin America

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2379

Thank you for reading our report. For customization inquiry or further information, please connect with us and we will ensure you get the report that meets your requirements.

Read More Reports:-

Zika Virus Testing Market @ https://www.biospace.com/article/zika-virus-testing-market-to-reach-usd-328-3-million-in-2028-says-reports-and-data/

C-Reactive Protein Testing Market @ https://www.biospace.com/article/c-reactive-protein-testing-market-size-to-reach-usd-1-93-billion-in-2028-says-reports-and-data-/

Disruptive Behavior Disorder Treatment Market @ https://www.biospace.com/article/disruptive-behavior-disorder-treatment-market-size-to-reach-usd-26-3-billion-in-2028-says-reports-and-data/

Dried Blood Spot Collection Cards Market @ https://www.biospace.com/article/dried-blood-spot-collection-cards-market-size-to-reach-usd-373-6-million-in-2028-says-reports-and-data-/

Hematologic Malignancies Market @ https://www.biospace.com/article/hematologic-malignancies-market-size-to-reach-usd-120-56-billion-in-2028-noted-reports-and-data/

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Tushar Rajput
Reports and Data
+91 90210 91709
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.